Diabetic Retinopathy Market To 2022 – Market Share, Growth, Trends: Grand View Research, Inc

Embed Size (px)

Text of Diabetic Retinopathy Market To 2022 – Market Share, Growth, Trends: Grand View Research, Inc

  • Diabetic Retinopathy Market By Type (Proliferative DR,

    Non-Proliferative DR) By Management (Anti-VEGF

    Therapy, Intraocular Steroid Injection, Laser Surgery,

    Vitrectomy) Is Expected To Reach USD 10.11 Billion By

    2022: Grand View Research, Inc.

    Global Diabetic Retinopathy Market is expected to reach USD 10.11 billion by 2022, according

    to a new study by Grand View Research Inc. Diabetic retinopathy is considered as a serious sight

    threatening complication that results due to long term diabetes. The treatment line selection for

    diabetic retinopathy depends on the severity of the condition and may require intraocular

    injections, anti VEGF drugs, laser surgery or vitrectomy. Increasing incidences of diabetes,

    rising geriatric population base and the growing demand for early detection are some high impact

    rendering drivers of the diabetic retinopathy market. Furthermore, improving healthcare

    infrastructure, rising demand for cost-effective and safe treatment and rising focus of market

    players on emerging nations such as India and China are also anticipated to propel market

    growth. Presence of supportive government initiatives such as the Queen Elizabeth Diamond

    Jubilee Trust, which is taking initiatives for increasing patient awareness levels in order to

    promote regular retinal screening and early laser surgery to prevent permanent visual impairment

    and Ophthalmic Society of South Africa which works towards the improvement of

    reimbursement policies are anticipated to fuel the growth of the diabetic retinopathy market over

    the forecast period.

    View summary of this report @ http://www.grandviewresearch.com/industry-

    analysis/diabetic-retinopathy-market

  • Global diabetic retinopathy market, by type, 2012-2022 (USD Million)

    Table of Content

    Chapter 1 Methodology and Scope

    1.1 Research Methodology

    1.2 Research Scope & Assumptions

    1.3 List of Data Sources

    Chapter 2 Executive Summary

    Chapter 3 Diabetic Retinopathy Industry Outlook

    3.1 Market segmentation

    3.2 Market size and growth prospects

    3.3 Diabetic retinopathy market dynamics

    3.4 Market driver analysis

    3.4.1 Increasing prevalence of diabetes

    3.4.2 Growing global geriatric population base

    3.4.3 Increasing incidences of blindness due to diabetes

    3.5 Market restraint analysis

    3.5.1 Lack of accurate diagnosis

    3.5.2 Extended approval time for drugs

    3.5.3 Lack of trained ophthalmologists

  • 3.6 Diabetic retinopathy: Epidemiology & guidelines

    3.7 Diabetic retinopathy: Pipeline overview

    3.8 Key Opportunities Prioritized

    3.9 Diabetic retinopathy company market share, 2014

    3.10 Industry analysis Porters

    3.11 Diabetic retinopathy PESTEL Analysis

    Chapter 4 Diabetic Retinopathy Type Outlook

    4.1 Diabetic retinopathy revenue share by type, 2014 & 2022

    4.2 Proliferative diabetic retinopathy

    4.2.1 Proliferative diabetic retinopathy market, 2012 2022 (USD Million)

    4.3 Non-proliferative diabetic retinopathy

    4.3.1 Non-proliferative diabetic retinopathy market, 2012 2022 (USD Million)

    Chapter 5 Diabetic Retinopathy Management Outlook

    5.1 Diabetic retinopathy revenue share, by management, 2014 & 2022

    5.2 Anti-VEGF therapy

    5.2.1 Anti-VEGF therapy market, 2012 2022 (USD Million)

    5.3 Intraocular steroid injection

    5.3.1 Intraocular steroid injection market, 2012 2022 (USD Million)

    5.4 Laser surgery

    5.4.1 Laser surgery market, 2012 2022 (USD Million)

    5.5 Vitrectomy

    5.5.1 Vitrectomy market, 2012 2022 (USD Million)

    Chapter 6 Diabetic Retinopathy Regional Outlook

    6.1 Diabetic retinopathy revenue share, by region, 2014 & 2022

    6.2 North America diabetic retinopathy market

    6.2.1 North America diabetic retinopathy market, 2012 2022 (USD Million)

    6.2.2 U.S. diabetic retinopathy market

    6.2.2.1 U.S. diabetic retinopathy market, 2012 2022 (USD Million)

    6.2.3 Canada diabetic retinopathy market

    6.2.3.1 Canada diabetic retinopathy market, 2012 2022 (USD Million)

    6.3 Europe diabetic retinopathy market

    6.3.1 Europe diabetic retinopathy market, 2012 2022 (USD Million)

    6.3.2 Germany diabetic retinopathy market

    6.3.2.1 Germany diabetic retinopathy market, 2012 2022 (USD Million)

    6.3.3 UK diabetics retinopathy

    6.3.3.1 UK diabetic retinopathy market, 2012 2022 (USD Million)

    6.4 Asia Pacific diabetic retinopathy market

    6.4.1 Asia Pacific diabetic retinopathy market, 2012 2022 (USD Million)

  • 6.4.2 China diabetic retinopathy market

    6.4.2.1 China diabetic retinopathy market, 2012 2022 (USD Million)

    6.4.3 Japan diabetic retinopathy market

    6.4.3.1 Japan diabetic retinopathy market, 2012 2022 (USD Million)

    6.5 Latin America diabetic retinopathy market

    6.5.1 Latin America diabetic retinopathy market, 2012 2022 (USD Million)

    6.5.2 Brazil diabetic retinopathy market

    6.5.2.1 Brazil diabetic retinopathy market, 2012 2022 (USD Million)

    6.6 MEA diabetic retinopathy market

    6.6.1.1 MEA diabetic retinopathy market, 2012 2022 (USD Million)

    6.6.2 South Africa diabetic retinopathy market

    6.6.2.1 South Africa diabetic retinopathy market, 2012 2022 (USD Million)

    Chapter 7 Competitive Landscape

    7.1 Bayer Healthcare

    7.1.1 Company Overview

    7.1.2 Financial Performance

    7.1.3 Product Benchmarking

    7.1.4 Strategic Initiatives

    7.2 Novartis AG

    7.2.1 Company Overview

    7.2.2 Financial Performance

    7.2.3 Product Benchmarking

    7.2.4 Strategic Initiatives

    7.3 Regeneron Pharmaceuticals Inc.

    7.3.1 Company Overview

    7.3.2 Financial Performance

    7.3.3 Product Benchmarking

    7.3.4 Strategic Initiatives

    7.4 Actavis PLC

    7.4.1 Company Overview

    7.4.2 Financial Performance

    7.4.3 Product Benchmarking

    7.4.4 Strategic Initiatives

    7.5 ThromboGenics

    7.5.1 Company Overview

    7.5.2 Financial Performance

    7.5.3 Product Benchmarking

    7.5.4 Strategic Initiatives

  • 7.6 Sirnaomics Incorporation

    7.6.1 Company Overview

    7.6.2 Financial Performance

    7.6.3 Product Benchmarking

    7.7 Genentech

    7.7.1 Company Overview

    7.7.2 Financial Performance

    7.7.3 Product Benchmarking

    7.7.4 Strategic Initiatives

    7.8 Glycadia Pharmaceuticals

    7.8.1 Company Overview

    7.8.2 Financial Performance

    7.8.3 Product Benchmarking

    7.9 Alimera Sciences

    7.9.1 Company Overview

    7.9.2 Financial Performance

    7.9.3 Product Benchmarking

    7.9.4 Strategic Initiatives

    7.10 Ampio Pharmaceuticals

    7.10.1 Company Overview

    7.10.2 Financial Performance

    7.10.3 Product Benchmarking

    7.10.4 Strategic Initiatives

    7.11 BCN Peptides

    7.11.1 Company Overview

    7.11.2 Financial Performance

    7.11.3 Product Benchmarking

    7.11.4 Strategic Initiatives

    7.12 Kowa Group

    7.12.1 Company Overview

    7.12.2 Financial Performance

    7.12.3 Pr